10-Q: Biora Therapeutics Reports Q1 2024 Financial Results, Cites Going Concern Uncertainty

Biora Therapeutics reports a net loss of $4.2 million for Q1 2024 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Biora Therapeutics, a clinical-stage biotechnology company, reported its financial results for the quarter ended March 31, 2024.
• The company is focused on developing oral biotherapeutics using its NaviCap and BioJet platforms.
• Revenues for the quarter were $542,000, compared to $2,000 in the same period last year.
• Research and development expenses decreased slightly to $7.005 million from $7.190 million.
• Selling, general, and administrative expenses increased to $9.053 million from $8.356 million.
• The net loss for the quarter was $4.2 million, or $0.14 per share, compared to a net loss of $17.441 million, or $1.59 per share, for the same period in 2023.
• The company had cash and cash equivalents of $10.6 million as of March 31, 2024.
• Management expresses substantial doubt about the company's ability to continue as a going concern within the next 12 months without additional funding.
• The company intends to raise additional capital through equity offerings, debt financings, or other sources.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the going concern warning and the need for additional funding, despite some improvements in revenue and net loss compared to the previous year. The company faces significant financial challenges and uncertainties.

Positives

• Revenue increased significantly compared to the same period last year, from $2,000 to $542,000.
• Net loss decreased substantially year-over-year, from $17.441 million to $4.2 million.
• The company sold its remaining investment in Enumera for $3.0 million in March 2024.

Negatives

• The company has a working capital deficit and an accumulated deficit of $955.1 million as of March 31, 2024.
• Management expresses substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's auditors have expressed doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funding, which may not be available on acceptable terms or at all.
• Failure to raise capital could force the company to delay, reduce, or eliminate research and development programs or other operations.
• The company faces risks associated with developing new product candidates, which is complex, costly, and uncertain.
• The company relies on a limited number of suppliers, and may not be able to find replacements or immediately transition to alternative suppliers on a cost-effective basis.
• The company operates in a highly competitive business environment.
• The company is subject to healthcare fraud and abuse regulations and enforcement.
• The company may be subject to claims that its employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.

Future Outlook

Management intends to raise additional capital through equity offerings, debt financings, or other sources, but there is no guarantee that such funding will be available on acceptable terms or at all. The company expects research and development expenses to remain flat in 2024.

Management Comments

• Management does not expect that the Company's current cash and cash equivalents will be sufficient to fund its operations for at least 12 months from the issuance date of the condensed consolidated financial statements for the three months ended March 31, 2024, and will require additional capital to fund the Company's operations.
• Management believes that the Company's liquidity position as of the date of this filing provides sufficient runway to achieve important research and development pipeline milestones.

Industry Context

The biotechnology industry is highly competitive and requires significant investment in research and development. Biora Therapeutics is focused on developing innovative drug delivery platforms, which could provide a competitive advantage if successful.

Comparison to Industry Standards

• It's difficult to directly compare Biora's results to industry standards without knowing the specific stage and focus of comparable companies.
• However, early-stage biotech companies often operate at a loss while investing heavily in R&D.
• A key metric to watch is the company's cash runway and its ability to secure additional funding, which is a common challenge for companies in this sector.
• Companies like Entera Bio and Oramed Pharmaceuticals are also working on oral delivery of large molecules, but their specific technologies and clinical progress differ.

Legal Proceedings

• The company is involved in a patent infringement suit filed by Ravgen, Inc. related to its discontinued historical laboratory developed test business.
• The company and plaintiffs agreed to settle the IPO litigation, subject to negotiation and entry into definitive and binding agreements and court approval, for an amount of $1.0 million.

Related Party Transactions

• Athyrium Capital Management, LP held $17.4 million aggregate principal amount of 2028 Convertible Notes and 35.9% of the company's common stock outstanding as of March 31, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation and potential need to reduce operations.
• Customers and partners face potential disruptions if the company is unable to continue operations.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company needs to achieve important research and development pipeline milestones.
• The company needs to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Biora Therapeutics, financial results, oral biotherapeutics, NaviCap, BioJet, going concern, convertible notes, clinical-stage biotechnology, drug delivery, capital raise